CereSpir Incorporated Announces Letter of Intent With Chiesi Farmaceutici SpA to License Worldwide Development and Commercialization Rights for CHF 5074 to CereSpir
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK and PARMA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today acknowledged the Companies have entered into a Letter of Intent and are negotiating a Licensing Agreement, whereby CereSpir will acquire the exclusive global development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia modulator that was discovered and developed by Chiesi researchers.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK and PARMA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today acknowledged the Companies have entered into a Letter of Intent and are negotiating a Licensing Agreement, whereby CereSpir will acquire the exclusive global development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia modulator that was discovered and developed by Chiesi researchers.
Help employers find you! Check out all the jobs and post your resume.